Popular tortilla chips urgently recalled for serious health risk
Frito-Lay has issued a recall on certain bags of Tostitos chips over an undeclared allergen.
The company issued a press release on Wednesday about a limited number of 13-ounce bags of Tostitos Cantina Traditional Yellow Corn Tortilla Chips being recalled in the U.S. The affected bags could mistakenly have nacho cheese tortilla chips, meaning they may contain an undeclared milk allergen.
The recalled product was distributed to a range of retailers across 13 states: Alabama, Florida, Georgia, Illinois, Indiana, Kentucky, Mississippi, North Carolina, Ohio, South Carolina, Tennessee, Virginia, and West Virginia.
The affected product has a UPC of 28400 52848 and a 'guaranteed fresh' date of May 20, 2025. The bags will also have certain manufacturing codes, which are listed in the press release.
Chip bags were first sold on March 7, with less than 1,300 bags included in the recall. There have not been any reported allergic reactions due to the product. No other Tostitos products have been affected by the recall.
According to the United States Department of Agriculture (USDA), consuming undeclared allergens 'may result in adverse health outcomes for certain individuals.' The most common undeclared allergens are wheat, shellfish, eggs, fish, peanuts, milk, tree nuts, and soybeans.
This isn't the first time that Frito-Lay has recalled a product due to an undeclared allergen. In November, a limited number of Lay's Classic Potato Chips bags were recalled because they may have contained undeclared milk, which Frito-Lay learned 'after being alerted through a consumer contact.'
The recalled product was sent to retail stores and distributors in Oregon and Washington, and it was available for purchase as early as November 3, 2024. Two months later, the Food and Drug Administration (FDA) elevated this recall to a Class I recall, which is 'a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.'
Within the last month, there has been a slew of food and drink recalls. Earlier this week, 864 cases of Coca-Cola — each of which had 12 cans — were recalled because they were contaminated with plastic. This means that more than 10,000 cans of soda were affected by the recall. The affected cases of Coca-Cola were distributed to retailers in Illinois and Wisconsin.
Last week, Aldi issued a voluntary recall on 400 cases of Happy Farm's Colby Jack Deli Sliced Cheese, which included 12 plastic pouches of blended Colby and Monterey cheese slices each. According to the FDA, the Aldi product may contain stainless steel fragments, and exposure to such contaminants could cause temporary health risks. It's unclear how the potential metal products got into the cheese.
Also earlier this month, Dessert Holdings, LLC announced that it was recalling Target brand Favorite Day's New York Style Cheesecake, sold in a six-ounce container with two slices of cake. The recall is due to mislabeled packaging, resulting in undeclared pecans in the products.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
FDA Approves Moderna's New COVID Vaccine With Restricted Use
The FDA has approved Moderna's new COVID-19 shot, an mRNA vaccine, with some limits on who can get it. The vaccine, called mNexspike, is for people who've previously received a COVID-19 shot and is mainly intended for adults ages 65 and older. People ages 12 to 64 may also get the shot if they have at least one medical condition that increases their risk for serious illness from COVID as defined by the CDC. COVID is caused by SARS-CoV-2 virus, which spreads from person to person and infects the airways. While some people may only have mild symptoms, older adults, or those with certain underlying health conditions such as heart disease, diabetes, obesity, cancer, or COPD, among other conditions, are at a higher risk for severe illness. Overall, COVID remains a serious health risk that caused over 47,000 deaths in the United States last year alone. Getting vaccinated is still one of the best ways to lower this risk, especially for those who are more likely to get seriously sick. Moderna said the FDA approved mNexspike based on results of a large study involving about 11,400 people ages 12 and older that showed it worked equally well and sometimes better than Spikevax, the original Moderna vaccine. The new shot showed about 9.3% better protection than Spikevax in people 12 and older and 13.5% better results in adults 65 and older. The mNexspike vaccine contains special genetic material (mRNA) that teaches the body to recognize parts of a key protein that helps the virus infect human cells. The new vaccine is based on the Omicron JN.1 COVID variant and helps your immune system make antibodies to protect you. Common side effects include pain, redness, or swelling from the injection, painfully swollen lymph nodes in the same arm, tiredness, headache, muscle or joint pain, chills, nausea, vomiting, and fever.
Fox News
an hour ago
- Fox News
FDA approves first AI tool to predict breast cancer risk
The U.S. Food and Drug Administration (FDA) has approved the first artificial intelligence (AI) tool to predict breast cancer risk. The authorization was confirmed by digital health tech company Clairity, the developer of Clairity Breast – a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. In a press release, Clairity shared its plans to launch the AI platform across health systems through 2025. Most risk assessment models for breast cancer rely heavily on age and family history, according to Clairity. However, about 85% of cases occur in women who have no family history of breast cancer, likely stemming from genetic mutations that occur because of aging, health agencies report. Traditional risk models have also been built on data from predominantly European Caucasian women, which Clairity said has not been "generalized well" to diverse backgrounds. The AI tool analyzes subtle images from a screening mammogram that correlate with breast cancer risk, then generates a "validated five-year risk score" and delivers it to healthcare providers, the company noted. Dr. Connie Lehman, Clairity founder and breast imaging specialist at Mass General Brigham, stressed the importance of mammograms in early cancer detection. "Now, advancements in AI and computer vision can uncover hidden clues in the mammograms – invisible to the human eye – to help predict future risk," she said in a press release. "By delivering validated, equitable risk assessments, we can help expand access to life-saving early detection and prevention for women everywhere." Dr. Robert A. Smith, senior vice president of early cancer detection science at the American Cancer Society, also commented in a statement that personalized, risk-based screening is "critical to improving breast cancer outcomes, and AI tools offer us the best opportunity to fulfill that potential." "This is the wave of the future. AI is going to be part of the equation, but it's not going to take over." "Clairity's FDA authorization is a turning point for more women to access the scientific advances of AI-driven cancer risk prediction," Larry Norton, founding scientific director of the Breast Cancer Research Foundation, wrote in another statement. "Breast cancer is rising, especially among younger women, yet most risk models often miss those who will develop the disease," he said. "Now we can ensure more women get the right care at the right time." More than 2.3 million women are diagnosed with breast cancer globally each year, including more than 370,000 in the U.S., despite "decades of progress," according to the Breast Cancer Research Foundation. Cases have particularly been on the rise among younger women under the age of 50. In a Tuesday appearance on "America's Newsroom," Fox News senior medical analyst Dr. Marc Siegel called Clairity's development "profound." "Just looking at a mammogram … sometimes [radiologists] will see things that aren't clear, they have to follow it over time," he said. "AI improves how focused and how predictive it is, [shown] very dramatically in studies." Siegel confirmed that radiologists across the country are generally in support of leveraging AI for cancer detection, especially in areas of the country that are "underserved" in terms of healthcare. For more Health articles, visit "In areas where you're relying on radiologists without special training, this is even more important," he said. "This is the wave of the future. AI is going to be part of the equation, but it's not going to take over."
Forbes
an hour ago
- Forbes
Access To Abortion Pill Mifepristone Could Be Threatened, Again
In this photo illustration, packages of mifepristone tablets are displayed at a family planning ... More clinic. Mifepristone is part of a two-drug regimen to induce an abortion in the first trimester of pregnancy in combination with the drug misoprostol. (Photo illustration by) The abortion pill mifepristone is in the crosshairs of politics again, as plaintiffs in several high-profile court cases together with Republican lawmakers push for restrictions. More importantly perhaps, the Food and Drug Administration is reviewing the regulation and labeling of mifepristone, a drug with a well-established safety and effectiveness record. In an unusual move, Secretary of Health and Human Services, Robert F. Kennedy Jr., issued a statement last month to the Senate Health, Education, Labor and Pensions Committee directing the FDA to 'do a complete review' of its regulations on mifepristone, a medication used in conjunction with misoprostol in two-thirds of abortions in the United States– which has been used by more than eight million people since its approval more than two decades ago. The FDA approved mifepristone in 2000 for medication abortion. Mifepristone is a drug that blocks progesterone, which is needed for a pregnancy to continue. When taken in conjunction with misoprostol, mifepristone ends early pregnancies (up to ten weeks following conception). Mifepristone can be safely administered at home when prescribed by a provider, The FDA has allowed people to take the medication outside of a clinic setting since 2021. And that same year, the FDA further eased several conditions with respect to the prescribing and sale of mifepristone. Specifically, the regulatory authority allowed for prescriptions to be issued through telemedicine visits in addition to shipments of the product by mail, as MedPage Today reported. It appears that rising numbers of abortions using prescription drugs in the past four years may be linked to the changes instituted by the FDA. In addition, the use of medication to end pregnancies could have also been triggered by the Supreme Court decision to overturn Roe v. Wade in 2022, as a Journal of the American Medical Association study describes. But it appears that besides wanting to subject mifepristone to a new FDA review, Kennedy also wishes to reinstate the in-person dispensing requirement, which would mean women must go to a clinic to obtain mifepristone. The Supreme Court preserved convenient access to mifepristone last year, throwing out a lawsuit that sought to reinstate the previous requirements. The justices' argument, however, largely hinged on questioning the physician plaintiffs' right to sue the FDA to restore conditions rather than the substance of the case. But then, earlier this year, The Hill reported that a Texas federal judge, Matthew Kacsmaryk, is allowing three Republican-led states to move forward with a lawsuit to restrict access to mifepristone. It's noteworthy that in 2023, Kacsmaryk temporarily halted FDA's approval of mifepristone altogether. In brief, it's unclear what will happen to access as cases move through the court system and findings from the review which Kennedy ordered are revealed. Mifepristone has been in use in Europe for nearly three decades with a minimal number of reported adverse events. And the drug has had a similar safety record in the U.S since its approval in 2000. Between September 2000 and December 2018, only 24 of the more than 3.7 million women who had undergone medicated abortions have died, according to the FDA. Overall, the adverse events rate is less than 1% and the drug is considered safer than, say, over-the-counter non-steroidal anti-inflammatory drugs and anti-histamines. At least 100 studies from around the world have examined the effectiveness and safety of mifepristone and misoprostol. All peer-reviewed studies concluded that the pills are a safe method for terminating a pregnancy. Yet there seems to be a non-peer-reviewed study that's at the center of a request for the FDA to assess mifepristone. It's from the conservative think tank, the Ethics and Public Policy Center. This particular study makes claims about what it views as a high rate of serious adverse events following medication abortions. Yet, the evidence from the U.S. and around the globe suggests a highly safe and effective medication. The FDA's mandate is to review the safety and efficacy of drugs based on clinical evidence. As such, the FDA is the federal authority for all pharmaceuticals distributed throughout the U.S., including mifepristone and misoprostol. And so, a series of court cases and Secretary Kennedy's request for another look at mifepristone set a potentially unsettling precedent in which the FDA's regulatory authority from past decisions is undermined. And it's not just mifepristone that's currently under renewed scrutiny. Consider, for example, that HHS is revisiting debunked theories of links between the measles, mumps and rubella vaccine and autism. The department has also spearheaded changes in COVID-19 vaccine recommendations that are not necessarily evidence-based, and inconsistent with prior and even current guidance from the Centers for Disease Control and Prevention.
